Abstract:ABSTRACT Objective Chemotherapy with 5-fluorouracil and oxaliplatin (FOLFOX or XELOX) or irinotecan (FOLFIRI) has become the mainstay of treatment for advanced colorectal cancer. Since not all patients would benefit from the chemotherapy they received, exploring factors that would predict better effectiveness remains meaningful for understanding the concept of individual treatment. The purpose of this study is to confirm the predictive role of a serial of SNPs, MTHFR C677T, A1298C, ABCG2 G34A and C421A, as well as the clinical features for the efficacy of first-line chemotherapy in advanced colorectal cancer. Methods Patients with advanced colorectal cancer and treated with first-line standard FOLFOX/XELOX or FOLFIRI regimens between January 2009 and May 2011 at Fudan University Shanghai Cancer Center were retrospectively studied. Gene polymorphisms of MTHFR and ABCG2 were detected using gene sequencing method, after DNA extraction from peripheral blood karyocytes and PCR amplification. Results Of all 154 patients, patients with 3 ∼ 4 of the favorable genotypes (MTHFR 677C/C, MTHFR 1298 A/A, ABCG2 G/A or A/A， and ABCG2 421C/A or A/A) had a longer PFS than those with 0 ∼ 2 above genotypes (9.8m vs. 7.5m, P = 0.013; HR = 0.627, 95%CI: 0.427 ∼ 0.920, P = 0.017) The radical resection of primary lesion was also found as an independent factor for both PFS (HR = 0.524, 95%CI: 0.320 ∼ 0.859, P = 0.010) and OS (HR = 0.291, 95%CI: 0.147 ∼ 0.575, P = 0.000). Interestingly, stratified univariate analysis revealed that patients with 2 ∼ 4 genotypes of MTHFR 677C/C、MTHFR 1298 A/C or C/C、ABCG2 34G/G and ABCG2 421C/A or A/A would benefit more from FOLFOX/XELOX than FOLFIRI as first-line chemotherapy (FOLFIRI: HR = 1.722, 95%CI: 1.026 ∼ 2.892, P = 0.040, compared with FOLFOX/XELOX). In contrast, patients with 0 or 1 above-mentioned genotype would have better outcomes if receiving FOLFIRI (FOLFIRI: HR = 0.422, 95%CI: 0.205 ∼ 0.870, P = 0.019, compared with FOLFOX/XELOX). Conclusions SNPs detection may play a predictive role in selecting first-line chemotherapy for advanced colorectal cancer patients. Radical resection of primary lesion is an independent factor for both PFS and OS. Disclosure All authors have declared no conflicts of interest.

Influence of Methylene Tetrahydrofolate Reductase C667T Gene Polymorphism on Survival Time of Adanced Gastric Cancer Patients Treated with 5-Fluorouracil-based Chemotherapy

Relationship Between Methylenetetrahydrofolate Reductase Polymorphism and Clinical Outcomes of Advanced Gastric Cancer Patients Treated with 5-Fu-based Chemotherapy

The Predictive Role of MTHFR and ABCG2 Single Nucleotide Polymorphisms on the Outcome of Advanced Colorectal Cancer Treated with First-Line Chemotherapy

Methylenetetrahydrofolate Reductase C677T Polymorphism Predicts Response and Time to Progression to Gemcitabine-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer in a Chinese Han Population

The Effects of Genomic Polymorphisms in One-Carbon Metabolism Pathways on Survival of Gastric Cancer Patients Received Fluorouracil-Based Adjuvant Therapy

Diets, polymorphisms of methylenetetrahydrofolate reductase, and the susceptibility of colon cancer and rectal cancer.

FOLIC ACID,METHIONINE,AND POLYMORPHISMS OF METHYLENETETRAHYDROFOLATE REDUCTASES AND SUSCEPTIBILITY OF COLORECTAL CANCER

Polymorphism of Methylenetetrahydrofolate Reductase Gene is Associated with Response to Fluorouracil-Based Chemotherapy in Chinese Patients with Gastric Cancer.

Relationship Between Polymorhisms of Related Genes in the Folic Acid Metabolic Pathway and the Survival of Gastric Cancer Patients Treated with Capecitabine Combined with Paclitaxel

Association of MTHFR C677T Polymorphism with 5-FU-Based Chemotherapy in Advanced Colorectal Cancer:A Meta-Analysis

Relationship Between Glutathione S-transferase P1 (GSTP1), X-ray Repair Cross Complementing Group 1 (XRCC1) and 5,10-Methylenetetrahydrofolate Reductase (5,10-MTHFR) Gene Polymorphisms and Response to Chemotherapy in Advanced Gastric Cancer.

Polymorphism in one-carbon metabolism pathway affects survival of gastric cancer patients: Large and comprehensive study.

Heterozygote Advantage of Methylenetetrahydrofolate Reductase Polymorphisms on Clinical Outcomes in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Platinum-Based Chemotherapy

An Integrated Analysis of the Association Between Ts Gene Polymorphisms and Clinical Outcome in Gastric and Colorectal Cancer Patients Treated with 5-Fu-based Regimens

Prognostic Value of the TS Genetic Polymorphisms and Therapeutic Effect in Advanced Esophageal Cancer Treated with Fluorouracil-Based Chemotherapy

Expression of Folate Receptor alpha and its Correlation with Folate, Methylenetetrahydrofolate Reductase Gene Polymorphisms and Biological Behaviour of Gastric Cancerous Tissue

Association of genetic polymorphis of thymidylate synthase and methylene tetrahydro folate reductase with therapeutic effect of pemetrexed for treating advanced lung adenocarcinoma patients

Diet folate, DNA methylation and polymorphisms in methylenetetrahydrofolate reductase in association with the susceptibility to gastric cancer

Effect of TP53 codon 72 and MDM2 SNP309 polymorphisms on survival of gastric cancer among patients who receiving 5-fluorouracil-based postoperative adjuvant chemotherapy

Gene polymorphism of 5-Fluoropyrimidine-related enzymes in cancer patients*

Single Nucleotide Polymorphisms (C677T and A1298C) in Methylenetetrahydrofolate Reductase Gene and Suscepcipility to Gastric Carcinoma